XY Capital Ltd Purchases 55,736 Shares of HUTCHMED (China) Limited Sponsored ADR $HCM

XY Capital Ltd lifted its position in shares of HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) by 115.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 104,130 shares of the company’s stock after purchasing an additional 55,736 shares during the quarter. HUTCHMED accounts for 1.1% of XY Capital Ltd’s investment portfolio, making the stock its 17th largest holding. XY Capital Ltd’s holdings in HUTCHMED were worth $1,120,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Amundi lifted its stake in shares of HUTCHMED by 4.0% in the first quarter. Amundi now owns 232,246 shares of the company’s stock valued at $3,474,000 after buying an additional 8,916 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of HUTCHMED during the first quarter worth about $365,000. State Street Corp raised its holdings in shares of HUTCHMED by 1.2% in the 4th quarter. State Street Corp now owns 321,305 shares of the company’s stock worth $4,283,000 after acquiring an additional 3,801 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of HUTCHMED by 3.0% in the 4th quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock worth $1,798,000 after acquiring an additional 3,900 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its position in HUTCHMED by 157.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 55,969 shares of the company’s stock valued at $746,000 after acquiring an additional 34,248 shares in the last quarter. Institutional investors own 8.82% of the company’s stock.

Key HUTCHMED News

Here are the key news stories impacting HUTCHMED this week:

• Positive Sentiment: HUTCHMED granted GSK exclusive rights outside Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate for solid tumors. The deal includes a $110 million upfront payment and could generate up to $1.295 billion in total milestone payments, plus royalties. Reuters article
• Positive Sentiment: The partnership validates HUTCHMED’s oncology pipeline through a major global pharmaceutical partner and could provide funding and development support for HMPL-A830. The drug is expected to enter clinical trials in the second half of 2026. HUTCHMED announcement
• Positive Sentiment: Daiwa Securities upgraded HCM from “hold” to “buy.” Panmure and Cavendish also reiterated “buy” ratings, citing the GSK deal and what they view as an overlooked valuation relative to HUTCHMED’s expanding oncology pipeline. Broker responses
• Neutral Sentiment: Management discussed the strategic partnership and licensing arrangement in an investor transcript, providing additional details on HMPL-A830’s development and the collaboration with GSK. Seeking Alpha transcript
• Negative Sentiment: HMPL-A830 remains an experimental therapy, so the milestone value is contingent on successful clinical development, regulatory approvals and commercialization. Investors may therefore continue to weigh substantial drug-development risk despite the sizable headline deal.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. The Goldman Sachs Group cut their price target on HUTCHMED from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Thursday, July 23rd. Morgan Stanley set a $13.60 target price on HUTCHMED in a report on Thursday, May 28th. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Bank of America decreased their price target on HUTCHMED from $20.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, July 7th. Finally, Daiwa Securities Group raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $14.87.

HUTCHMED Stock Performance

NASDAQ HCM opened at $14.09 on Friday. HUTCHMED has a 52-week low of $9.77 and a 52-week high of $18.30. The company has a 50-day simple moving average of $11.76 and a 200 day simple moving average of $12.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64.

HUTCHMED (NASDAQ:HCM) last released its earnings results on Thursday, July 30th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.09). The business had revenue of $139.14 million for the quarter, compared to analysts’ expectations of $304.16 million. Analysts forecast that HUTCHMED will post 0.33 earnings per share for the current fiscal year.

HUTCHMED Profile

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.